Expanding Chaetocin-Based Therapies to Novel Hearing Loss Prevention and Treatment Applications

Publication ID: 24-11857551_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Expanding Chaetocin-Based Therapies to Novel Hearing Loss Prevention and Treatment Applications,” Published Technical Disclosure No. 24-11857551_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857551_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,551.

Summary of the Inventive Concept

This inventive concept leverages the core technology of chaetocin-based compounds to prevent and treat hearing loss in new, high-impact industries, including aviation, military, music, construction, and sports.

Background and Problem Solved

While the original patent focuses on preventing and treating hearing loss caused by chemotherapeutic agents, this new inventive concept addresses the unmet need for effective hearing loss prevention and treatment solutions in diverse industries, where loud noise exposure is a significant occupational hazard.

Detailed Description of the Inventive Concept

The inventive concept involves administering chaetocin-based compounds to protect the inner ear cells from death caused by loud noise exposure in various settings. For instance, in pilots, chaetocin can be administered to prevent noise-induced hearing loss. In soldiers, a pharmaceutical composition comprising chaetocin can be administered prior to exposure to explosive noise. Similarly, in musicians, a topical composition comprising chaetocin can be applied to the outer ear to prevent hearing loss. In construction workers, a noise-cancelling earpiece with a dispenser for administering chaetocin can be used. In swimmers, a topical composition comprising chaetocin can be applied to the outer ear prior to swimming.

Novelty and Inventive Step

The new claims introduce novel applications of chaetocin-based compounds in diverse industries, which were not originally considered in the original patent. The inventive step lies in recognizing the potential of these compounds to prevent and treat hearing loss in these new settings, and developing specific formulations and delivery methods tailored to each industry's unique needs.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include using different analogs of chaetocin, varying the administration routes and dosages, or combining chaetocin with other therapeutic agents to enhance its efficacy. Additionally, the inventive concept can be adapted for use in other industries, such as manufacturing, emergency response, or transportation, where noise exposure is a significant risk.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including aviation, military, music, construction, and sports, where hearing loss prevention and treatment are critical concerns. The market for hearing loss prevention and treatment solutions is substantial, and this inventive concept offers a novel, effective, and targeted approach to addressing this need.

Field of Art

Pharmaceutical compositions for hearing protection, specifically focused on otoprotective agents and methods of preventing hearing loss across various noise exposure scenarios

Person of Ordinary Skill (PHOSITA) Profile

A pharmacologist or medical researcher with expertise in drug delivery, hearing protection technologies, and pharmaceutical formulations, possessing knowledge of noise-induced hearing loss mechanisms and protective compound strategies

Obviousness Rationale

A PHOSITA would recognize that the core mechanism of chaetocin for protecting inner ear cells from damage is universally applicable across different noise exposure contexts. The fundamental scientific principle of preventing cellular death through chaetocin remains consistent, regardless of the specific noise source or professional environment. The variations in administration method and target industry represent predictable design choices that would be obvious extensions of the original hearing loss prevention technology.

Obvious Combinations & Variations

Source Patent Element
Method of preventing hearing loss caused by chemotherapeutic agents using chaetocin
PTD Variation
Extending chaetocin protection to noise-induced hearing loss in specific professional environments
Obviousness Reasoning
Known mechanism of cellular protection is directly transferable, representing a predictable application of the existing therapeutic approach
Source Patent Element
Protecting inner ear cells from death
PTD Variation
Developing industry-specific delivery methods like topical compositions and specialized dispensing devices
Obviousness Reasoning
Routine pharmaceutical engineering to adapt known protective compounds to different administration routes and contexts
Source Patent Element
Pharmaceutical composition for preventing hearing loss
PTD Variation
Creating targeted formulations for pilots, soldiers, musicians, construction workers, and swimmers
Obviousness Reasoning
Finite and predictable set of high-noise professional environments where hearing protection is critical
Source Patent Element
Use of chaetocin to prevent cellular death in inner ear
PTD Variation
Exploring analog compounds and combination therapies for enhanced hearing protection
Obviousness Reasoning
Standard pharmaceutical research approach of exploring structural variations and combination strategies
Source Patent Element
Method of administering protective compound to prevent hearing loss
PTD Variation
Integrating protective compounds with existing hearing protection technologies like noise-cancelling earpieces
Obviousness Reasoning
Obvious combination of known protective technologies representing standard engineering design optimization
35 U.S.C. § 103 Summary: Based on US Patent 11857551's disclosure of chaetocin for hearing loss prevention, the present publication demonstrates that a person of ordinary skill in the art would find the extended applications of chaetocin across various noise-exposure environments to be obvious and predictable variations of the original invention, thus rendering subsequent claims in this domain anticipated and non-patentable.

Original Patent Information

Patent NumberUS 11,857,551
TitleMethods for the prevention and treatment of hearing loss
Assignee(s)Ting Therapeutics LLC